Search - tctmd.com

Displaying 941 - 960 of 1227

Sort: Relevancy | Date

Presentation TCT 2016

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients!

Presenter: Andreas Baumbach, David Hildick-Smith, Wilson Y. Szeto

November 01, 2016

Presentation TCT 2016

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? Yes, Even if Only to Avoid a Disfiguring Sternotomy!

Presenter: Andreas Baumbach, David Hildick-Smith, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

Comprehensive CT Algorithm Before TAVR

Presenter: Jeroen J. Bax, Jonathon A. Leipsic, James K. Min, João L Cavalcante

November 01, 2016

News Conference News TCT 2016

TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function

Todd Neale

November 01, 2016

News Industry News TCT 2016

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

November 01, 2016

News Industry News TCT 2016

Dedicated Stent Study Conducted in Women and Minority Assesses Risks of Adverse Cardiovascular Events Following Coronary Stent Procedures

November 01, 2016

Presentation TCT 2016

Early Feasibility of a Percutaneous Tricuspid Valve Annuloplasty System for Symptomatic Chronic Functional Tricuspid Regurgitation: 30-Day Results From the SCOUT Trial

Presenter: Ted Feldman, David Hildick-Smith, Rebecca T. Hahn

November 01, 2016

Presentation TCT 2016

One-Year Outcomes from the Early Feasibility Study of the Harmony Trans-Catheter Pulmonary Valve

Presenter: Ted Feldman, David Hildick-Smith, Lee N. Benson

November 01, 2016

Presentation TCT 2016

One-Year Outcomes from the Early Feasibility Study of the Harmony Trans-Catheter Pulmonary Valve

Presenter: Ted Feldman, David Hildick-Smith, Lee N. Benson

November 01, 2016

Presentation TCT 2016

Percutaneous Suture Based PFO Closure with the NobleStitch EL Device: Initial Multicenter Clinical Experience

Presenter: Ted Feldman, David Hildick-Smith, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

Prospective Single Center FIH Clinical Trial to Evaluate the Safety and Effectiveness of a Septal Occluder with Bioresorbable Framework in Patients with Clinically Significant ASD or PFO

Presenter: Ted Feldman, David Hildick-Smith, Kolja Sievert

November 01, 2016

Presentation TCT 2016

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

Presenter: William A. Gray, Stephan Windecker, John R. Laird Jr.

October 31, 2016

Presentation TCT 2016

ACT I Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Klaus D. Mathias

October 31, 2016

Presentation TCT 2016

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

Presenter: William A. Gray, Stephan Windecker, Kenneth Rosenfield

October 31, 2016

Presentation TCT 2016

CTSN Severe MR 2-Year Critique: Pro and Con

Presenter: William A. Gray, Stephan Windecker, Patrick M. McCarthy

October 31, 2016

Presentation TCT 2016

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Presenter: William A. Gray, Stephan Windecker, Michael Argenziano

October 31, 2016

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Complications of Structural Heart Disease Intervention

Presenter: George S. Hanzel, Mauricio G. Cohen

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

Advertisement

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients!

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? Yes, Even if Only to Avoid a Disfiguring Sternotomy!

Comprehensive CT Algorithm Before TAVR

TAVR Provides ‘Acceptable’ Outcomes in Low-Flow, Low-Gradient Aortic Stenosis Patients With Poor Ventricular Function

Patients With Sever Aortic Stenosis And Intermediate Surgical Risk Show Similar Late Quality of Life Outcomes Following Either Transcatheter or Surgical Aortic Valve Replacement

Dedicated Stent Study Conducted in Women and Minority Assesses Risks of Adverse Cardiovascular Events Following Coronary Stent Procedures

Early Feasibility of a Percutaneous Tricuspid Valve Annuloplasty System for Symptomatic Chronic Functional Tricuspid Regurgitation: 30-Day Results From the SCOUT Trial

One-Year Outcomes from the Early Feasibility Study of the Harmony Trans-Catheter Pulmonary Valve

One-Year Outcomes from the Early Feasibility Study of the Harmony Trans-Catheter Pulmonary Valve

Percutaneous Suture Based PFO Closure with the NobleStitch EL Device: Initial Multicenter Clinical Experience

Prospective Single Center FIH Clinical Trial to Evaluate the Safety and Effectiveness of a Septal Occluder with Bioresorbable Framework in Patients with Clinically Significant ASD or PFO

Trial #9 - The Essentials ofIN.PACT SFA: 3-year Outcomes of a Paclitaxel-Coated Balloon for Femoropopliteal Lesions

ACT I Critique: Pro and Con

Trial #8 - The Essentials ofThe ACT I Trial: Carotid Stenting vs Surgery In Asymptomatic Patients

CTSN Severe MR 2-Year Critique: Pro and Con

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Complications of Structural Heart Disease Intervention

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content